In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmion's Euro Bet Pays Off

Executive Summary

Celgene's $2.9 billion cash and stock offer for Pharmion proves that Pharmion's decision to tackle Europe--not a popular choice among US-based spec pharma--has paid off handsomely. Pharmion is Celgene's European partner on Thalomid; now Celgene gets 100% of the drug's economics right before launch. The deal may have come as a surprise to Wall Street, but it makes sense.
Advertisement

Related Content

Clovis Taps Into Rich "A" Round, Grabs Licensing Rights to Improved Gemcitabine
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2007
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2007
Biopharma: Reviewing 2007 to Forecast 2008
Eisai Surprise Winner in MGI Auction
Europe's New Spec Pharma Models
Europe's New Spec Pharma Models
Building a Business in Drug Safety
Biotech's Euro-Marketing Gambit
Biotech's Euro-Marketing Gambit

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002886

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel